RECURRENT MYELODYSPLASTIC SYNDROME

This study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…

This study is for adults with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatment. Participants receive a strong chemotherapy combination (CLAG-M or FLAG-Ida) followed immediately by a stem cell transplant from a donor. T…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see if the combination can shrink or control the cancer. The trial is for adults 60 and old…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). The drug is an antibody that may slow cancer growth. About 76 adults will receive injections to see if it improves blood c…

This early-phase trial tests a combination of three drugs (pembrolizumab, decitabine, and venetoclax) in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the …

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 p…

This study tests a combination of two drugs—CPX-351 (a stronger form of standard chemo) and quizartinib (a targeted therapy)—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combo can bette…

This early-stage study tests a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with certain blood cancers (MDS and AML). The goal is to find a safe dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment…

This early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…